trial

Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia

NCTId NCT01793935
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 68 (actual)
Sponsored by K.N. Roy Chengappa
Primary completion 2016-07-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
68 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2013-04
Primary completion
2016-07-07
Eligibility
ALL · 18 Years · 75 Years

Interventions & indications

Drugs
Sensoril®

Sponsors

K.N. Roy ChengappaLead Sponsor

Investigators

1
KN Roy Chengappa, MDPrincipal Investigator

Sites

1 total
Pittsburgh, United States

Facts & assertions

4 sourced
Enrollment
68
Phase
NA
Primary Completion Date
2016-07-07
Status
COMPLETED
relationships
The graph out of here
drug
Sensoril®
drug
lead_sponsor
K.N. Roy Chengappa
company
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
Schizophrenia
indication
investigator
KN Roy Chengappa, MD
person